Contractor directory
UEI HX79BD6YQ521 · CAGE 5JGC8

Synedgen, Inc.

Synedgen, Inc. received $0 in federal prime contract obligations in the 12 months ending Oct 5, 2026, down 100.0% from $1.9M the year before, and $21.7M since FY2022. Its largest customer is the Department of Health and Human Services.

See 1 contracts ending in the next 18 months ↓
Obligations, latest 12 months
$0
down 100.0% vs. $1.9M
Since FY2022
$21.7M
3 awards
Awards with activity
1
Latest 12 months
Most recent action
Sep 24, 2026
First seen Aug 17, 2022

Contractor details

Unique Entity ID (UEI)
HX79BD6YQ521
CAGE code
5JGC8
Headquarters
Claremont, CA
Business size
Small Business

As recorded on this UEI's most recent prime contract action in USAspending.gov. Confirm current registration and certifications in SAM.gov.

Obligations by fiscal year

Net prime contract obligations by federal fiscal year.

FY2022
$550K
FY2023
$0
FY2024
$19.2M
FY2025
$1.9M
FY2026
$0

Top agencies

Funding agencies ranked by obligations since FY2022.

Funding agencyLatest 12 moSince FY2022
Department of Health and Human Services$0$18.8M
Department of Defense$0$2.8M

Top NAICS codes

Industry codes agencies recorded on this contractor's awards, since FY2022.

NAICSIndustryLatest 12 moSince FY2022
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)$0$21.7M

What it sells

Product and service codes (PSC) on this contractor's awards, since FY2022.

PSCDescriptionSince FY2022
AN13Health R&D services; Health Care services; Experimental Development$18.8M
AN12Health R&D services; Health Care services; Applied Research$2.3M
AN11Health R&D services; Health Care services; Basic Research$550K

Contracts ending in the next 18 months

This contractor's largest awards whose current period of performance ends soon. Options and extensions often move these dates.

AwardAgencyObligatedCurrent end
75A50124C00047
Department of Health and Human Services
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE…
$18.8MMay 31, 2027

Recent awards

This contractor's newest prime contract awards, most recent first.

AwardAgencyObligatedAwarded
75A50124C00047
Department of Health and Human Services
ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE…
$16.9MSep 26, 2024
HT942524C0049
Department of Defense
SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION…
$2.3MSep 19, 2024
W81XWH22C0061
Department of Defense
AWARD OF SYNEDGEN'S DHA SBIR PHASE III FOLLOW-ON MEDICAL R&D CONTRACT FOR "DEVELOPMENT OF TECHNOLOGIES THAT CONTROL SCAR FORMATION AFTER BURN INJURIES"
$550KAug 17, 2022

Prime contracts (award types A–D) from USAspending.gov through Oct 5, 2026. Subcontracts are not included. Net obligations include deobligations and corrections.

Ready to win more?

Ready to connect your pursuit work?

GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.